机译:一些胰高血糖素样肽-1受体激动剂(GLP-1 RA)是否能减少2型糖尿病的大血管并发症?利拉鲁肽在糖尿病中的作用和作用评论:心血管结局结果评估 (LEADER) 试验
Aristotle Univ Thessaloniki, Hippocrat Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki;
Univ Athens, Laiko Gen Hosp, Sch Med, Propedeut Dept Internal Med 1, Athens, Greece;
Glucagon-like-peptide-1 receptor agonists; dipeptidyl peptidase 4 inhibitors; type 2 diabetes mellitus; cardiovascular disease; heart failure;
机译:Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom
机译:Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs): A pooled analysis of type 2 diabetes trials
机译:The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
机译:Go4it; study design of a randomised controlled trial and economic evaluation of a multidisciplinary group intervention for obese adolescents for prevention of diabetes mellitus type 2